HeartFlow Executive Stock Transaction Overview
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy HTFL?
Source: Fool
- Transaction Overview: HeartFlow's Chief Medical Officer Rogers Campbell exercised 67,017 options and immediately sold 64,533 shares of common stock for approximately $1.66 million, indicating routine liquidity management under a pre-arranged plan.
- Ownership Changes: This transaction reduced Campbell's direct common stock holdings from 288,591 to 78,518 shares, a decrease of about 72.8%, while indirect holdings remained unchanged, suggesting he still maintains significant control over the company.
- Future Potential: Campbell retains direct stock options, providing substantial future conversion potential and signaling ongoing alignment with share price performance, despite the significant reduction in direct holdings.
- Company Growth Outlook: HeartFlow is guiding for 2026 revenue between $218 million and $222 million, reflecting continued growth in its AI-driven cardiac imaging platform, and despite ongoing net losses, investors remain optimistic about its strong revenue growth trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.690
Low
35.00
Averages
38.60
High
40.00
Current: 24.690
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartFlow Executive Stock Transaction Overview
- Transaction Overview: HeartFlow's Chief Medical Officer Rogers Campbell exercised 67,017 options and immediately sold 64,533 shares of common stock for approximately $1.66 million, indicating routine liquidity management under a pre-arranged plan.
- Ownership Changes: This transaction reduced Campbell's direct common stock holdings from 288,591 to 78,518 shares, a decrease of about 72.8%, while indirect holdings remained unchanged, suggesting he still maintains significant control over the company.
- Future Potential: Campbell retains direct stock options, providing substantial future conversion potential and signaling ongoing alignment with share price performance, despite the significant reduction in direct holdings.
- Company Growth Outlook: HeartFlow is guiding for 2026 revenue between $218 million and $222 million, reflecting continued growth in its AI-driven cardiac imaging platform, and despite ongoing net losses, investors remain optimistic about its strong revenue growth trajectory.
See More
HeartFlow CMO Executes Options and Sells Shares
- Trading Overview: HeartFlow's CMO, Rogers Campbell, exercised 67,017 options and sold 64,533 shares on March 19, 2026, generating approximately $1.66 million at an average price of $25.69 per share, indicating a strategic liquidity management approach by the executive.
- Shareholding Changes: This transaction reduced Campbell's direct common stock holdings by 22.36%, while he retains 145,540 shares in indirect holdings, suggesting sustained confidence in the company's future; the transaction was executed under a pre-arranged plan, reflecting routine management operations.
- Financial Performance Highlights: HeartFlow reported full-year 2025 revenue of about $176 million, a 40% year-over-year increase, with fourth-quarter revenue reaching $49.1 million and gross margins nearing 80%, showcasing strong market demand for its AI-powered cardiac imaging platform.
- Future Outlook: Management guides for 2026 revenue between $218 million and $222 million, implying continued double-digit growth; despite ongoing net losses, robust revenue growth provides investor confidence, indicating that investments in commercialization and R&D are sustainable.
See More
Capricorn Investment Group Acquires HeartFlow Shares Worth $48.18 Million
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025, with an estimated transaction value of $48.18 million, indicating confidence in the company's future prospects.
- Asset Impact: This acquisition accounts for 5.83% of Capricorn's 13F reportable assets, although HeartFlow does not rank among the fund's top five holdings, reflecting a selective investment strategy.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, marking a robust 40% year-over-year increase, yet it reported a net loss of $24.4 million, highlighting ongoing efforts to manage costs effectively.
- Market Risks: Despite HeartFlow's price-to-sales ratio nearing a low since its IPO, investors should proceed with caution as the company remains unprofitable and its stock price has declined by 10.7% in 2026.
See More
Capricorn Investment Group Acquires HeartFlow Shares
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025 for approximately $48.18 million, reflecting confidence in the company's future prospects.
- Asset Allocation: The new HeartFlow position represents 5.83% of Capricorn's reportable assets under management, highlighting its significance in a portfolio that includes only seven holdings.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, a robust 40% year-over-year increase, yet reported a net loss of $24.4 million, indicating ongoing efforts to manage costs effectively.
- Market Opportunity: With a price-to-sales ratio of 12 near its IPO low, HeartFlow's declining share price suggests a potential buying opportunity for investors looking to capitalize on future growth despite the inherent risks of a newly public company.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartFlow Executive Stock Transaction Overview
- Transaction Overview: HeartFlow's Chief Medical Officer Rogers Campbell exercised 67,017 options and immediately sold 64,533 shares of common stock for approximately $1.66 million, indicating routine liquidity management under a pre-arranged plan.
- Ownership Changes: This transaction reduced Campbell's direct common stock holdings from 288,591 to 78,518 shares, a decrease of about 72.8%, while indirect holdings remained unchanged, suggesting he still maintains significant control over the company.
- Future Potential: Campbell retains direct stock options, providing substantial future conversion potential and signaling ongoing alignment with share price performance, despite the significant reduction in direct holdings.
- Company Growth Outlook: HeartFlow is guiding for 2026 revenue between $218 million and $222 million, reflecting continued growth in its AI-driven cardiac imaging platform, and despite ongoing net losses, investors remain optimistic about its strong revenue growth trajectory.
See More
HeartFlow CMO Executes Options and Sells Shares
- Trading Overview: HeartFlow's CMO, Rogers Campbell, exercised 67,017 options and sold 64,533 shares on March 19, 2026, generating approximately $1.66 million at an average price of $25.69 per share, indicating a strategic liquidity management approach by the executive.
- Shareholding Changes: This transaction reduced Campbell's direct common stock holdings by 22.36%, while he retains 145,540 shares in indirect holdings, suggesting sustained confidence in the company's future; the transaction was executed under a pre-arranged plan, reflecting routine management operations.
- Financial Performance Highlights: HeartFlow reported full-year 2025 revenue of about $176 million, a 40% year-over-year increase, with fourth-quarter revenue reaching $49.1 million and gross margins nearing 80%, showcasing strong market demand for its AI-powered cardiac imaging platform.
- Future Outlook: Management guides for 2026 revenue between $218 million and $222 million, implying continued double-digit growth; despite ongoing net losses, robust revenue growth provides investor confidence, indicating that investments in commercialization and R&D are sustainable.
See More
Capricorn Investment Group Acquires HeartFlow Shares Worth $48.18 Million
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025, with an estimated transaction value of $48.18 million, indicating confidence in the company's future prospects.
- Asset Impact: This acquisition accounts for 5.83% of Capricorn's 13F reportable assets, although HeartFlow does not rank among the fund's top five holdings, reflecting a selective investment strategy.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, marking a robust 40% year-over-year increase, yet it reported a net loss of $24.4 million, highlighting ongoing efforts to manage costs effectively.
- Market Risks: Despite HeartFlow's price-to-sales ratio nearing a low since its IPO, investors should proceed with caution as the company remains unprofitable and its stock price has declined by 10.7% in 2026.
See More
Capricorn Investment Group Acquires HeartFlow Shares
- Share Acquisition: Capricorn Investment Group purchased 1,661,601 shares of HeartFlow in Q4 2025 for approximately $48.18 million, reflecting confidence in the company's future prospects.
- Asset Allocation: The new HeartFlow position represents 5.83% of Capricorn's reportable assets under management, highlighting its significance in a portfolio that includes only seven holdings.
- Financial Performance: HeartFlow generated $176 million in revenue for 2025, a robust 40% year-over-year increase, yet reported a net loss of $24.4 million, indicating ongoing efforts to manage costs effectively.
- Market Opportunity: With a price-to-sales ratio of 12 near its IPO low, HeartFlow's declining share price suggests a potential buying opportunity for investors looking to capitalize on future growth despite the inherent risks of a newly public company.
See More
